drug resistance | pharmaphorum

Skip to main content

Thursday 26 December 2024

twitter linkedin facebook rss

User account menu

Subscribe

Channels

Content type

Categories

Categories

Sort by

Order

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

close

Channels

Content type

Categories

Categories

Sort by

Order

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

Sign up

twitter linkedin facebook rss

Sign in

drug resistance

News

remdesivir_image

Gilead says Veklury should work against COVID-19 variants

Gilead Sciences says its antiviral Veklury should be effective against the new, more contagious COVID-19 variants discovered in the UK and South Africa.

News

Coronavirus vaccine: how pharma is picking up the pace

Pfizer/BioNTech say COVID-19 vaccine works against UK varian...

Laboratory studies have confirmed that antibodies stimulated by Pfizer and BioNTech’s COVID-19 vaccine can neutralise the new, more transmissible variant of SARS-CoV-2 identified in the UK.

Partner Content

600x77

Partner Content

Superbugs: Exclusive Interviews Released with ABAC Therapeut...

Q&A's Out Ahead of Superbugs 2018

Partner Content

Superbugs and Superdugs

Partner Content

Agenda released for SMi’s 20th Annual Superbugs European Sho...

Agenda released for 20th Annual Superbugs Event

Editor's Picks

Novo completes $16.5bn takeover of Catalent

UnitedHealth killing suspect gets first-degree murder charge

Novo sets aside $1.2bn for rare diseases plant

Lilly's Alzheimer's drug Kisunla is cleared in China

PBM reform looms in end-of-year US legislation package

News

Daiichi and AZ pull Dato-DXd filing in Europe too

Daiichi and AZ pull Dato-DXd filing in Europe too

AstraZeneca and Daiichi Sankyo have decided to voluntarily withdraw their EU marketing application for Dato-DXd in lung cancer.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

The AI effect in pharma commercial strategy: From data to real-time insight & actions

Sponsored

The AI effect in pharma commercial strategy: From data to re...

Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Subscribe

rss facebook linkedin twitter

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2024, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2024, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company